on January 2, 2019 Obalon Therapeutics, Inc. will transition Kelly Huang, Ph.D. to the role of Chief Executive Officer and Andy Rasdal to the role of Chairman of the Board.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2805 USD | +34.99% | +51.46% | +12.33% |
05-15 | Transcript : ReShape Lifesciences Inc., Q1 2024 Earnings Call, May 15, 2024 | |
05-15 | Earnings Flash (RSLS) RESHAPE LIFESCIENCES Posts Q1 Revenue $1.9M, vs. Street Est of $2.1M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.33% | 4.87M | |
+6.88% | 219B | |
+10.63% | 192B | |
+18.16% | 142B | |
+29.70% | 111B | |
+2.09% | 65.32B | |
+14.14% | 52.45B | |
+3.01% | 49.8B | |
+4.64% | 43.43B | |
+1.45% | 35.95B |
- Stock Market
- Equities
- RSLS Stock
- News ReShape Lifesciences Inc.
- Obalon Therapeutics, Inc. Announces Executive Appointments